Safety of Nirmatrelvir/Ritonavir in Pediatrics and Adolescents: Pharmacovigilance Study of VigiBase
Journal of Pharmacoepidemiology and Risk Management · 31.03.2026 · 18 (1) · 61-76
DOI: 10.56142/perm.25.0025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacoepidemiology and Risk Management, erschienen am 31.03.2026. Verfasst von So-Young Kim und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kim, S., & Kim, J. H. (2026). Safety of Nirmatrelvir/Ritonavir in Pediatrics and Adolescents: Pharmacovigilance Study of VigiBase. Journal of Pharmacoepidemiology and Risk Management, 18(1), 61-76. https://doi.org/10.56142/perm.25.0025
Vancouver
Kim S, Kim JH. Safety of Nirmatrelvir/Ritonavir in Pediatrics and Adolescents: Pharmacovigilance Study of VigiBase. Journal of Pharmacoepidemiology and Risk Management. 2026;18(1):61-76. doi:10.56142/perm.25.0025
BibTeX
@article{Kim2026,
author = {Kim, So-Young and Kim, Ju Hwan},
title = {Safety of Nirmatrelvir/Ritonavir in Pediatrics and Adolescents: Pharmacovigilance Study of VigiBase},
journal = {Journal of Pharmacoepidemiology and Risk Management},
year = {2026},
volume = {18},
number = {1},
pages = {61--76},
doi = {10.56142/perm.25.0025}
}
EUVIMED